Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Colin Baigent(University of Oxford), Faı̈ez Zannad(Inserm), Silvio E. Inzucchi(Yale University), Deepak L. Bhatt(Brigham and Women's Hospital), Brendon L. Neuen(Royal North Shore Hospital), Martina Brueckmann, Jennifer B. Green, Javed Butler(University of Mississippi Medical Center), John J.V. McMurray(Western Infirmary), Vlado Perkovic(The George Institute for Global Health), Natalie Staplin(Medical Research Council), David Z.I. Cherney(Sunnybrook Health Science Centre), Marc S. Sabatine(Brigham and Women's Hospital), Jonathan Emberson(University of Oxford), Hiddo J.L. Heerspink(University Medical Center Groningen), Christoph Wanner(University of Würzburg), Finnian R. McCausland, Kenneth W. Mahaffey(Cardiovascular Institute of the South), David Preiss(Medical Research Council), Milton Packer(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Scott D. Solomon(Brigham and Women's Hospital), Muthiah Vaduganathan(Harvard University), Kaitlin J. Mayne, David C. Wheeler(University Medical Center Groningen), Doreen Zhu, Darren K. McGuire, Bruce Neal(Imperial College London), William G. Herrington, Martin Landray, Chih‐Chin Liu, Alistair Roddick, Sibylle J. Hauske(Heidelberg University), Richard Haynes, Stephen D. Wiviott, Meg Jardine(Royal North Shore Hospital), Parminder K. Judge, Sarah Y A Ng, Stefan D. Anker(German Centre for Cardiovascular Research)
Cited by 969
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k